"Epoetin Alfa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients.
| Descriptor ID |
D000068817
|
| MeSH Number(s) |
D12.644.276.374.410.240.150.500 D12.776.395.240.150.750 D12.776.467.374.410.240.150.500 D23.529.374.410.240.150.750
|
| Concept/Terms |
Epoetin Alfa- Epoetin Alfa
- Alfa, Epoetin
- Recombinant 1-165 Erythropoietin, Glycoform Alpha
- Recombinant 1 165 Erythropoietin, Glycoform Alpha
|
Below are MeSH descriptors whose meaning is more general than "Epoetin Alfa".
Below are MeSH descriptors whose meaning is more specific than "Epoetin Alfa".
This graph shows the total number of publications written about "Epoetin Alfa" by people in this website by year, and whether "Epoetin Alfa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 3 | 2 | 5 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Epoetin Alfa" by people in Profiles.
-
Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary. Expert Rev Hematol. 2020 11; 13(11):1175-1188.
-
Cost-minimization analysis between intravenous iron sucrose and iron sucrose similar in hemodialysis patients. Expert Rev Pharmacoecon Outcomes Res. 2020 Jun; 20(3):281-287.
-
Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease. JCI Insight. 2019 04 23; 5.
-
Cause and Timing of Death and Subgroup Differential Effects of Erythropoietin in the EPO-TBI Study. J Neurotrauma. 2018 01 15; 35(2):333-340.
-
Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients?. Clin Nephrol. 2017 Oct; 88(10):190-197.
-
Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis. J Nephrol. 2018 06; 31(3):321-332.
-
Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g-Formula to Anemia Management Strategies. Health Serv Res. 2018 06; 53(3):1900-1918.
-
Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. BMJ Open. 2017 03 10; 7(3):e011637.
-
History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology. Am J Nephrol. 2017; 45(3):235-247.